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Background/Aims
Opioid-induced constipation (OIC) is the most common gastrointestinal (GI) side effect to opioid treatment. Opioid receptor 
antagonists against OIC have been introduced, but their efficacy has not been directly compared to conventional laxatives. Our aim 
was to compare symptoms and objective parameters of gut function in an experimental model of OIC during treatment with the 
opioid antagonist naloxone and oxycodone in prolonged-release (PR) formulation versus oxycodone plus macrogol 3350.
Methods
In this randomized, double-blind, crossover trial 20 healthy men received a 5-day treatment of combined PR oxycodone/naloxone 
or PR oxycodone plus macrogol 3350. Regional GI transit times and segmental colorectal transit were assessed with the Motilis 
3D-Transit electromagnetic capsule system. Colorectal volumes were determined by MRI. OIC symptoms were assessed with validated 
questionnaires, along with stool frequency and consistency. 
Results
Total colorectal volume did not change after 5 days’ treatment with PR oxycodone/naloxone (941 vs 1036 mL; P = 0.091), but 
increased significantly after PR oxycodone plus macrogol treatment (912 vs 1123 mL; P < 0.001). Neither regional GI transit times 
nor segmental colorectal transit differed between the treatments (all P > 0.05). The Patient Assessment of Constipation Symptom 
Questionnaire abdominal symptoms score was lower during PR oxycodone/naloxone compared to PR oxycodone plus macrogol (0.2 vs 
3.2; P = 0.002). Stool frequency was lower during PR oxycodone/naloxone compared to PR oxycodone plus macrogol (4.2 vs 5.4; P = 
0.035).
Conclusions
PR oxycodone plus macrogol increases colorectal volume, but does not improve GI transit compared to PR oxycodone/naloxone. 
However, PR oxycodone/naloxone results in a lower abdominal symptom burden, despite higher stool frequency during macrogol 
treatment.
(J Neurogastroenterol Motil 2018;24:119-127)
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Introduction  
Treatment with opioids is essential in patients with severe 
acute and chronic pain. However, opioid treatment often results in 
substantial gastrointestinal (GI) side effects, collectively referred to 
as opioid-induced bowel dysfunction (OIBD).1 These effects are 
mediated by binding of opioids to peripheral μ-opioid receptors in 
the gut, thereby disturbing normal GI motility and function.2 The 
result is symptoms such as dry mouth, gastroesophageal reflux, 
vomiting, bloating, abdominal pain, anorexia, hard stools, and 
incomplete evacuation. The most common symptom is however 
opioid-induced constipation (OIC), occurring in 15% to 90% of 
the patients.3 
Recommended first-line treatment for OIC is conventional 
laxatives.4 However, there are no randomized controlled, double-
blind trials to support their efficacy in OIC. The pathophysiology 
behind OIC differs from that of functional constipation and OIC 
may not respond adequately to conventional laxatives.5 Hence, 
many patients with OIC have GI symptoms despite the use of 2 
or more laxatives.5,6 Furthermore, laxatives often cause side effects, 
such as bloating, abdominal distension, rumbling, flatulence, and 
gastroesophageal reflux.7 
Several opioid receptor antagonists directly targeting the patho-
physiology behind OIC have been introduced. Initial results have 
been promising,8,9 but head-to-head comparison of these opioid 
antagonists versus conventional laxatives has not been conducted. 
Furthermore, considerable diversity in outcome measures used in 
previous trials makes comparison of efficacy difficult. 
The recently suggested definition for OIC by the Rome IV 
working group is an important step towards easier comparison 
of trials evaluating OIC treatment,10 but these should ideally also 
include objective assessments. We have previously developed a 
model of OIC in healthy volunteers and shown that oxycodone 
causes symptoms of OIC, prolongs regional GI transit times,11 and 
increases colorectal volumes.12 The model for OIC in healthy vol-
unteers allows for interventional studies of OIC not influenced by 
confounders such as comorbidity, activity level or concomitant drug 
that can all cause constipation and hence make studies in patients 
difficult to interpret. 
We hypothesized that combined prolonged-release (PR) oxyco-
done/naloxone tablets would be more effective than PR oxycodone 
plus conventional laxative treatment with macrogol 3350 in prevent-
ing oxycodone-induced OIC. To test this hypothesis, the aims of the 
study were to evaluate how the 2 treatments affected (1) regional GI 
transit times and segmental colorectal transit, (2) segmental colorec-
tal volumes, (3) symptoms of OIC, and (4) associations between 
symptoms and the objective assessments.
Materials and Methods  
Study Design
This randomized, double-blind, double-dummy, crossover trial 
was conducted in compliance with the principles of the Internation-
al Conference on Harmonisation on Good Clinical Practice of the 
European Union, the Danish Health and Medicines Authority and 
approved by the local Ethical Committee (N-20130030). Partici-
pants were enrolled from September 2015 to June 2016 at Mech-
Sense, Department of Gastroenterology and Hepatology, Aalborg 
University Hospital. Data reported in the present paper are part of 
a larger protocol that simultaneously evaluated treatment of experi-
mentally induced OIBD on a number of parameters (unpublished 
data). The full trial is registered at www.clinicaltrialsregister.eu (Eu-
draCT No. 2013-001540-60).
Participants were all healthy volunteers treated for 5 days (one 
period) with (1) combined PR oxycodone/naloxone tablets or (2) 
PR oxycodone tablets and co-administered macrogol (polyethyl-
ene glycol) 3350 powder for oral solution. There was a wash-out 
period of at least 9 days, before the participants were crossed over 
to the other treatment. Participants were randomized by means of a 
computer-generated block-randomization list. The personnel who 
generated the randomization list were not otherwise involved in the 
study. Assignment to each randomization number was done chron-
ologically in the same order participants were enrolled. Dropouts 
were replaced using mirror-randomization. The sample size calcu-
lation was based on a previous study using the same endpoints.13 
Performing a sample size calculation with a mean difference of 0.5 
days in total transit time between treatments, a variance of 0.4, a 
power of 95% and a at 0.05 in a two-sided test, the calculation esti-
mated a sample of 19 as appropriate. Thus, we choose a sample size 
of 20 participants.
Both treatment periods commenced with fasting baseline as-
sessments of segmental colorectal volumes with MRI and ques-
tionnaires (Fig. 1). The first dose of the drugs was administered 
orally after baseline measurements (day 1, Mondays) and then 
repeated every 12th hour until the morning of day 5 (Fridays). Fol-
lowing administration of the first dose after baseline assessments, 
the participants were discharged from the research facility and 
returned to their daily activities. Three hours after administration 
of the first dose, a standardized meal (375 kcal, 11.4 g fat, 1.8 g 
fiber) was ingested and immediately after the meal was finished, 
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the electromagnetic 3D-Transit capsule (see below) was ingested 
with a glass of water. Participants returned to the research facilities 
on days 2, 3, and 4 for dosing, questionnaires, and so that emitted 
signals from the capsules could be monitored in real-time. This 
was done to confirm retention or expulsion of the capsule. Subjects 
were asked to refrain from hard physical work and sports. On day 
5, the measurements described for the baseline day were repeated. 
If the 3D-Transit capsule had not been expelled on day 5, the MRI 
was cancelled, as the capsule is not MRI compatible. Oxycodone 
dose in both periods was 5 mg twice daily on day 1 and 10 mg twice 
daily day 2 through day 4 and finalizing with 10 mg on the morn-
ing of day 5 administered at least 1 hour before measurements. One 
sachet of macrogol 3350 powder for oral solution or matching pla-
cebo (dextrose) was co-administered with every dosing. Each sachet 
contained 13.125 g macrogol 3350, 350.7 mg sodium chloride, 
178.5 mg sodium bicarbonate, and 46.6 mg potassium chloride. 
To mask the different taste of macrogol or placebo each sachet was 
diluted in in 250 mL Rynkeby orange juice (Rynkeby, Denmark).14 
PR oxycodone/naloxone tablets and matching placebo tablets were 
provided by Mundipharma Research Ltd, Cambridge, England. 
Macrogol and matching placebo were supplied by The Capital 
Region Pharmacy, Herlev, Denmark. For readability, the PR oxy-
codone/naloxone treatment period will from now on be referred to 
as “PR naloxone treatment” and the PR oxycodone plus macrogol 
3350 treatment period as “macrogol treatment.”
Study Participants
Eligible participants were healthy, male volunteers with neither 
current symptoms nor history of GI disease. Participants under-
went a screening session where informed consent was obtained, 
and a physician evaluated their medical history to ensure that all 
inclusion and exclusion criteria were fulfilled. If found eligible, the 
participants were enrolled in the study.
Inclusion criteria were: (1) signed written informed consent 
declaration, (2) capable of reading and understanding Danish, (3) 
male of Northern European descent, (4) understanding of the study 
procedures, (5) age 20-60 years, (6) healthy, and (7) opioid naïve. 
The exclusion criteria were: (1) known allergy towards opioids, (2) 
participation in any other studies within 14 days of enrolment, (3) 
planned medical/surgical treatment within the study duration, (4) a 
need to operate heavy machinery or motor vehicles during the study, 
(5) any previous or current drug abuse, (6) non-removable pierc-
ings or metal implants, (7) daily alcohol or nicotine consumption, (8) 
any known disease that may influence the results, and (9) the use of 
prescribed medicine and/or herbal medicine.
Study Outcomes
Gastrointestinal transit times
Total and segmental GI transit times (gastric emptying, small 
intestinal transit, and colorectal transit) were determined using the 
3D-Transit system.15 In short, the 3D-Transit system is a minimally 
invasive, ambulatory system, which relies on small, wireless tele-
metric capsules that are ingested and an extracorporeal, portable 
detector that tracks the precise position and general orientation of 
the capsule from ingestion to expulsion.16,17 Accordingly, changes 
in position, velocity of movements, and orientation of the capsules, 
reflecting gut contractile activity, and progression dynamics, may be 
Figure 1. Timeline for one study period. MRI scans were done in fasting state at the same time at baseline and day 5. The 3D-Transit capsule was 
ingested 3 hours after administration of the first dose. Daily verification of the 3D-Transit capsule progression was done to confirm retention or 
expulsion from the body. 
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studied with respect to anatomical information.16,18 
Segmental transit times of the colon (cecum/ascending colon, 
transverse colon, descending colon, and rectosigmoid colon) were 
evaluated based on visualization and determination of the trajectory 
transversed in the colon by the 3D-Transit capsule, as described 
previously.11 If the capsule was not expelled on day 5, the recording 
was stopped, and the time of last confirmed signal from the capsule 
was used as a proxy for earliest possible expulsion time.
Segmental colorectal volumes 
Segmental colorectal volumes were determined by MRI scans 
acquired using a 3T GE scanner (GE Signa HDxt, General Elec-
tric, Milwaukee, WI, USA). Approximately 40 contiguous coronal 
T2-weighted images with 4 mm slice thickness and in-plane resolu-
tion of approximately 0.9 × 0.9 mm were obtained covering the 
entire colon and rectum. Segmental colorectal volumes (cecum/
ascending colon, transverse colon, descending colon, and rectosig-
moid colon) were determined using semi-automatic in-house data 
analysis software, as described in detail previously.19,20 
Questionnaires
The participants were asked to fill in 4 validated GI question-
naires:21 (1) the Bowel Function Index (BFI); a 3-item question-
naire specifically developed to assess OIC, (2) the Gastrointestinal 
Symptom Rating Scale (GSRS); covering 15 items assigned to 5 
dimensions: gastroesophageal reflux, abdominal pain, dyspepsia, 
diarrhea, and constipation, (3) the Patient Assessment of Constipa-
tion Symptom Questionnaire (PAC-SYM); comprised of 12 items 
assigned to 3 subscales: stool symptoms, rectal symptoms, and 
abdominal symptoms, and (4) the Bristol Stool Form Scale evaluat-
ing stool frequency and consistency. The BFI and GSRS were ad-
ministered at baseline and day 5, while the PAC-SYM and Bristol 
Scale were used to assess the dynamic changes of the general bowel 
function and thus assessed daily. 
Statistical Methods 
Data are presented as means (95% confidence interval) unless 
otherwise indicated, and was assessed for normality and handled ac-
cordingly with parametric or nonparametric statistics. 
Data from regional GI transit times and segmental colorectal 
transit were non-parametrically distributed, and are presented as 
medians and interquartile range. Wilcoxon signed rank test was 
used to compare the 2 treatments for non-parametric variables. 
Segmental colorectal volumes, BFI, PAC-SYM, Bristol Scale 
scores, and GSRS were analyzed with repeated measures mixed 
models. PAC-SYM and segmental colorectal volume data were 
baseline corrected. PAC-SYM total score and the 3 subscale scores 
(abdominal symptoms, stool symptoms, and rectal symptoms) were 
analyzed in separate models. Data from the GSRS were analyzed as 
total score and syndrome dimension scores in separate models (ab-
dominal pain, reflux, indigestion, diarrhea, and constipation). For 
mixed models with significant interaction, Bonferroni-adjusted post 
hoc tests were applied for multiple comparisons. 
Pearson’s product-moment correlation coefficient was used to 
identify linear associations between symptoms and objective assess-
ments of constipation as determined by transit times and colorectal 
volumes. 
All reported P-values were two-tailed and values less than 0.05 
were considered significant. Data were analyzed using Stata version 
14.2 (StataCorp LP, College Station, TX, USA).
Results  
Study Participants
Twenty participants with a median age of 24 years (range: 18 to 
40 years), a mean height of 182 cm (181-185 cm), and mean body 
mass index of 23.8 kg/m2 (22.6-25.0 kg/m2) were enrolled in the 
study. All participants completed both study periods. The 2 treat-
ment periods were separated by a median of 45 days (range: 31-59 
days).
Study Outcomes
Gastrointestinal transit times 
Forty capsules were ingested (1 per period for each subject). 
Due to technical problems in 1 case, it was only possible to deter-
mine total GI transit. Capsule retention on day 5 occurred in 9 re-
cordings (5 during PR naloxone treatment and 4 during macrogol). 
In cases with capsule retention, the last confirmed signal from the 
capsule was used as proxy for the earliest possible expulsion time. 
Thus, it was possible to calculate the total transit in 40 recordings 
and regional GI transit in 39 recordings. No adverse events were 
registered. 
There were no differences in total, regional GI, or segmental 
colorectal transit times between treatments (all P > 0.05) (Table 1). 
Segmental colorectal volumes
Five scans on day 5 in the PR naloxone period and 4 scans on 
day 5 in the macrogol period were not done due to retention of the 
3D-Transit capsule. In addition, 3 scans were missed due to techni-
cal problems with the MRI scanner; one on day 5 in each of the 
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treatment periods, and 1 at baseline in the macrogol period. Thus, 
68 scans were available for further analysis with scans at all time 
points in 12 participants. Data form all 68 scans were included in 
the statistical model. There were no differences in total volume or 
in any of the segments between the 2 baselines (all P > 0.1) (Table 
2), or in the PR naloxone period (baseline vs day 5) (Table 2). In 
the macrogol period (baseline vs day 5), total colorectal volume and 
all segmental volumes increased significantly (Table 2). Baseline 
corrected volumes increased significantly for macrogol compared to 
PR naloxone for the entire colorectum and for the rectosigmoid (Fig. 
2). An example of a fully segmented colorectum is shown in Figure 3. 
Questionnaires
No difference was found for BFI score between baselines (P = 
0.791) or between PR naloxone and macrogol on day 5 (P = 0.666) 
Figure 3. Fully segmented colorectal 
volumes for one representative partici-
pant on the 2 baseline days, and on day 
5 during the 2 treatments. Numbers 
next to the colorectal segments on day 
5 in each treatment period are change 
in volume (in mL) from baseline. PR, 
prolonged-release.
PR naloxone
Baseline Day 5
Macrogol
+1
24
32
+35
+31
+82
Baseline Day 5
+1 +5
Figure 2. Change in total and segmental colorectal volumes during 
the 2 treatments. Data are presented as means ± SEM. *P = 0.001. 
**P = 0.005. PR, prolonged-release.
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Table 1. Total and Segmental Gastrointestinal Transit Times (in 
Hours) During the 2 Treatments 
PR naloxone Macrogol P-value
Gastric emptying time 3.5 (2.6-6.8) 3.2 (2.3-4.9) 0.334
Small intestine transit time 5.3 (4.7-6.3) 5.8 (4.6-8.1) 0.091
Cecum and ascending colon 7.2 (3.6-19.5) 9.0 (6.6-19.9) 0.554
Transverse colon 4.5 (1.6-9.5) 6.8 (2.8-9.1) 0.331
Descending colon 1.9 (0.1-7.7) 4.9 (1.1-10.4) 0.917
Rectosigmoid colon 11.7 (7.9-24.7) 10.3 (1.2-19.2) 0.125
Colorectal transit time 39.6 (26.6-74.3) 38.2 (30.9-61.2) 0.872
Total GI transit time 46.0 (34.8-84.7) 46.6 (41.6-70.7) 0.793
PR, prolonged-release; GI, gastrointestinal.
Data are presented as medians (interquartile range). 
Table 2. Segmental Colorectal Volumes (in mL) for Baseline and Day 5 in Both Treatment Periods
Cecum/ascending colon Transverse colon Descending colon Rectosigmoid Total
PR naloxone (baseline) 220 ± 25 258 ± 42 187 ± 32 276 ± 60 941 ± 108
PR naloxone (day 5) 257 ± 41 295 ± 47 210 ± 51 273 ± 71 1036 ± 176
Change from baseline 26 ± 25 (+17%) 
(P = 0.156)
48 ± 37 (+14%)
(P = 0.161)
38 ± 38 (+12%)
(P = 0.384)
-18 ± 36 (-1%)
(P = 0.904)
94 ± 88 (+10%) 
(P = 0.087)
Macrogol (baseline) 216 ± 39 270 ± 59 184 ± 55 242 ± 55 912 ± 158
Macrogol (day 5) 277 ± 53 328 ± 51 231 ± 44 287 ± 52 1123 ± 145
Change from baseline 54 ± 31 (+27%)
(P = 0.005)
87 ± 47 (+22%)
(P = 0.006)
70 ± 35 (+25%)
(P = 0.022)
63 ± 49 (+19%)
(P = 0.026)
274 ± 113 (+23%)
(P < 0.001)
PR, prolonged-release.
Data are presented as means ± 95% confidence interval (change from baseline in percent). 
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(Fig. 4A). Hence, there was no difference between the treatment 
periods. BFI score increased significantly from baseline to day 5 
during both PR naloxone (P < 0.001) and macrogol (P < 0.001) 
(Fig. 4A). 
For the baseline corrected PAC-SYM scores, there was no dif-
ference in total score during PR naloxone compared to macrogol 
(8.5 ± 6.9 vs 4.8 ± 3.9; P = 0.102). For the PAC-SYM sub-
scales, the per period abdominal symptom score was lower in the 
PR naloxone period compared to macrogol (P = 0.002) (Fig. 4B). 
There were no differences in PAC-SYM rectal symptoms score 
between the treatments (-0.4 ± 1.1 vs 0.0 ± 1.9; P = 0.525) or 
constipation symptoms score (5.0 ± 3.4 vs 5.4 ± 3.8; P = 0.834). 
No difference was found for GSRS total score at baseline (P = 
0.913), or between treatments on day 5 (PR naloxone vs macrogol) 
(P = 0.827). For the GSRS syndrome dimension scores, abdomi-
nal symptoms increased from baseline to day 5 both during PR 
naloxone (+38%, P < 0.001) and macrogol (+21%, P = 0.020), 
but there was no difference between the treatments on day 5 (P = 
0.171). GSRS constipation score also increased significantly from 
baseline to day 5 both during PR naloxone (+6%, P < 0.001) and 
macrogol (+16%, P < 0.001), but there was no difference between 
the treatments on day 5 (P = 0.933). No other differences for 
GSRS were found (all P > 0.05).
The cumulated per period stool frequency was lower in the PR 
naloxone period compared to macrogol (4.2 ± 1.2 vs 5.4 ± 1.5; 
P = 0.035). Post hoc analysis revealed a difference on day 4 with a 
mean number of bowel movements of 0.9 in the PR naloxone pe-
riod versus 1.9 in the macrogol period (P < 0.001), but not on any 
of the other days (all P > 0.05) (Table 3). The mean Bristol stool 
type per period did not differ between PR naloxone and macrogol 
treatment (3.2 ± 0.4 vs 3.5 ± 0.5; P = 0.141). However, pairwise 
comparison of types between days during the 2 treatments revealed 
a significant difference on day 5, but not on any of the other days (all 
P > 0.05) (Table 3).
Associations
There were no associations between baseline corrected segmen-
tal colorectal volumes in any of the colorectal segments and ques-
tionnaire scores during either of the treatment periods (all Pearson’s 
r < ± 0.5; all P > 0.05).
Discussion  
This study evaluated regional GI transit times, segmental 
colorectal transit and volume, and GI symptoms during treatment 
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Figure 4. Development of gastrointestinal symptoms during the 2 treatments. Panel (A) shows development in Bowel Function Index (BFI) scores 
during the 2 treatments. There was no difference between the treatment periods. Panel (B) illustrates the baseline corrected Patient Assessment of 
Constipation (PAC-SYM) abdominal subscale scores during the treatments. The P-values are the Bonferroni-adjusted pairwise comparison of 
scores between days. Data are presented as means ± SEM. PR, prolonged-release. 
Table 3. Bristol Stool Form Scale Data (Daily Stool Frequency and 
Stool Type During the 2 Treatment Periods) 
Day 1 Day 2 Day 3 Day 4 Day 5
Frequency
   PR naloxone 0.6 ± 0.4 1.0 ± 0.4 1.2 ± 0.5 0.9 ± 0.3 0.5 ± 0.2
   Macrogol 0.5 ± 0.4 1.1 ± 0.5 1.3 ± 0.5 1.9 ± 0.6 0.6 ± 0.4
   P-value 0.559 0.845 0.696 < 0.001 0.696
Type
   PR naloxone 3.3 ± 0.7 3.5 ± 0.4 3.3 ± 0.7 3.5 ± 0.5 2.8 ± 0.8
   Macrogol 3.8 ± 0.4 3.4 ± 0.5 3.3 ± 0.5 3.5 ± 0.5 4.6 ± 0.6
   P-value 0.999 0.999 0.999 0.999 0.001
PR, prolonged-release.
Data are presented as means  ± 95% confidence interval. 
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with PR oxycodone/naloxone versus PR oxycodone plus macrogol 
3350. Colorectal volumes did not change during PR oxycodone/
naloxone treatment, but increased significantly in all segments dur-
ing PR oxycodone plus macrogol 3350 treatment. However, there 
were no differences in neither regional GI transit times nor segmen-
tal colorectal transit between treatments. Self-assessed GI symptom 
scores increased during both treatments, but the Patient Assessment 
of Constipation abdominal symptom score was lower in the PR 
oxycodone/naloxone period. 
Gastrointestinal Transit
Regional GI and segmental colorectal transit times were similar 
during the 2 treatment periods and comparable to transit during 
PR oxycodone alone (44 hours) in a previous experimental study 
from our group using the same oxycodone dose.11 For the PR 
naloxone period, our results are somewhat in contrast to a scinti-
graphic transit study by Smith et al,22 who showed that a single dose 
of 10 mg PR naloxone in combination with 20 mg PR oxycodone 
significantly reduced colonic transit compared to PR oxycodone 
alone. The reason for this discrepancy between the studies remains 
obscure, but may reflect the different methodologies used to assess 
transit times. In our study, measurements rely on transport of a non-
digestable solid, whereas Smith et al22 used a radiolabelled resin to 
measure transit. Moreover, the dosage regimen and the drugs dif-
fered between the studies.
Interestingly, macrogol treatment did not decrease transit time 
in comparison to the study where we administered PR oxycodone 
alone.11 The pathophysiological basis for OIC is caused by hyper-
polarization of enteric neurons and reduction in neurotransmitter 
release thereby inhibiting motility.23 Macrogol acts by increasing 
stool volume through increased hydration, thereby triggering co-
lonic motility.24 However, these actions have primarily been studied 
patients with functional constipation. As macrogol does not target 
the underlying pathophysiology of OIC, this may explain why there 
is no significant improvement in transit times.
Segmental Colorectal Volumes
Change in total colorectal and rectosigmoid volumes were sig-
nificantly higher after macrogol treatment compared to PR nalox-
one. This is not surprising, considering that macrogol is an osmotic 
laxative.24 However, coupled with the transit times it is interesting 
that the increased stool volume during macrogol did not result in 
a decrease in gastrointestinal transit compared to the PR naloxone 
period. Moreover, the transit in the macrogol period was similar to 
our previous study where PR oxycodone was administered alone.11 
In a study by Lam et al,25 the authors used MRI scans to measure 
intestinal volumes, transit, and motility in response to a single dose 
of macrogol in patients with either functional constipation or ir-
ritable bowel syndrome with constipation. Functional constipation 
patients showed slower transit and greater ascending colon volumes. 
Using objective MRI biomarkers, they could distinguish functional 
constipation from irritable bowel syndrome with constipation with a 
specificity of 95%. Compared with the current study, it is plausible 
that OIC shares pathophysiological traits with slow transit consti-
pation, but the volume increase is inadequate to stimulate colonic 
motility and thus transit. 
Questionnaires 
BFI scores increased similarly during both treatments; from 
5 to 27 points during PR naloxone treatment and from 6 to 29 
points during macrogol. Previous studies have demonstrated that 
a 12 point increase can be interpreted as clinically meaningful,26 
but a total score of ≤ 30 is considered to indicate a normal bowel 
function.27 In our previous study, the BFI score increased 34 points 
during PR oxycodone treatment.11 Thus, both treatments seem 
to have a minor positive effect on BFI compared to our previous 
study, although the difference may not be significant. It could also 
be argued that neither of the treatments was successful in reducing 
the constipating effects of oxycodone assessed by the BFI scores.
The PAC-SYM questionnaire showed that the abdominal 
symptom subscale score was lower in the PR naloxone period. This 
may reflect that the PAC-SYM––as a whole––evaluates a broader 
spectrum of more pronounced GI symptoms, as rectal burning, 
bleeding, or tearing are also part of the questionnaire.21 Opioid treat-
ment results not only in constipation, but a range of other symptoms 
such as reflux, bloating, abdominal distension and cramping, nau-
sea, anorexia and therefore the term OIBD is more appropriate.28,29 
As the abdominal symptom subscale score covers symptoms as 
discomfort in the stomach, bloating, and stomach cramps that are 
consistent with the more broadly description of the pan-intestinal 
effects of opioids, it appears the participants are better treated with 
PR naloxone than macrogol. However, these abdominal symptoms 
may also be ascribed to side effects from the macrogol treatment.30 
The higher GSRS scores showed a similar pattern with significant 
increases for abdominal symptoms and constipation, but not for any 
of the other dimensions.
Stool frequency was lower in the PR naloxone period. Inter-
estingly, PAC-SYM abdominal symptom score was higher in the 
macrogol period, despite the participants’ higher stool frequency, 
illustrating that stool frequency does not necessarily result in lower 
symptom scores.
Segmental colorectal volumes and were not associated ques-
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tionnaires scores. This may reflect the challenging clinical picture 
of constipation where patients’ perception of symptoms seldom cor-
respond to objective findings, complicating effective alleviation of 
symptoms.31
Study Limitations and Strengths 
The cancelled MRI scans on day 5 due to 3D-Transit capsule 
retention––resulting in only 12 participants with full MRI data-
sets––is a limitation of the study. Despite this, our results clearly 
indicate that the significant increase in total colorectal and rectosig-
moid volumes during macrogol treatment did not improve transit 
compared to PR naloxone. As Figure 2 also illustrates, the volumes 
in the ascending, transverse, and descending colon were all numeri-
cally higher during macrogol treatment, albeit this was not statisti-
cally significant. The missing scans on day 5 significantly reduce 
the statistical power of the calculations, which may explain the lack 
of significance in these colorectal segments. In concert, these results 
suggest that increase in volume do not necessarily result in a de-
crease in transit time.
Exclusion of women from the study may have introduced gen-
der bias. This was done in order to avoid confounding alterations in 
gut function related to the menstrual cycle.32 However, functional 
constipation and irritable bowel syndrome are more prevalent in 
women, suggesting greater susceptibility to alterations in gut func-
tion.33,34
The experimental design may not mirror the clinical picture of 
chronic pain patients, who are usually prescribed higher doses of 
opioids and treated for longer periods. However, previous animal 
studies suggest that while tolerance may develop to the analgesic 
effects and upper GI motility upon repeated morphine administra-
tion, tolerance does not develop in the colon.35,36 To the authors 
knowledge no similar studies exist in humans, but if the preclinical 
results can be translated to humans, the outcomes of a clinical study 
would likely be either similar to ours or potentially more profound 
due to the longer treatment and/or higher doses. Nonetheless, in 
clinical studies, confounding factors that can affect gut function, 
such as concomitant drug use, immobility, dehydration, anxiety, 
depression, and anorexia are difficult to avoid and may bias results. 
When these factors are controlled for in an experimental setting, the 
results may consequently reflect the effect of the treatment of inter-
est to a greater extent.
Conclusion  
Colorectal volumes did not change during PR oxycodone/nal-
oxone, but increased significantly in all segments during oxycodone 
plus macrogol 3350 treatment. Self-assessed GI symptom scores in-
creased during both treatments. However the abdominal symptom 
score was lower in the PR oxycodone/naloxone period, despite lower 
stool frequency compared to the oxycodone plus macrogol period. 
These results indicate that neither oral PR oxycodone/naloxone nor 
oxycodone plus macrogol are able to reverse opioid-induced delay 
in GI transit. However, PR oxycodone/naloxone results in a lower 
abdominal symptom burden than oxycodone plus macrogol con-
sistent with a higher colorectal volume load in the oxycodone plus 
macrogol period. The objective methods presented may also be use-
ful in future comparative studies treatment of constipation of other 
causes. 
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